Makers Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024
+17.2%−12.5%+15.4%
+133.1%+41.3%+9.0%
+59.0%+21.9%+0.9%
——−9.3%
−137.0%+166.8%−11.3%
+3.0%−17.1%+1.6%
−2.9%+9.0%−11.7%
−27.4%+48.2%−115.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

MAKERSL₹192.45

Makers Laboratories Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOCMcap ₹114 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Revenue Growth—+15.4-12.5+17.2
EBITDA Growth—+9.0+41.3+133.1
EBIT Growth—+0.9+21.9+59.0
Net Income Growth—-9.3——
EPS Growth—-11.3+166.8-137.0
Total Assets Growth—+1.6-17.1+3.0
Total Equity Growth—-11.7+9.0-2.9
Cash from Operations Growth—-115.2+48.2-27.4
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.